Archives
-
L-NMMA Acetate in NO Pathway Research
2026-09-22
L-NMMA acetate enables controlled suppression of nitric oxide synthase activity in cell-based, regenerative, and disease-model experiments. Its strongest use-case is mechanistic testing: pair NOS inhibition with viability, NO, cGMP, and phenotype measurements to determine whether a biological effect depends on the NOS signaling pathway.
-
Phosphatase Inhibitor Cocktail 3: Practical Guide
2026-09-21
Phosphatase Inhibitor Cocktail 3 helps limit dephosphorylation during extraction of animal tissues and cultured-cell lysates for phosphoprotein analysis. It is intended for sample-preparation workflows, not as a complete protease inhibitor system, universal inhibitor for every phosphatase, or validated live-cell treatment.
-
Anti-Epileptic Drugs and Human PON1 Inhibition
2026-09-21
The reference study compares five commonly used antiepileptic drugs as inhibitors of purified human serum paraoxonase-1 (hPON1), combining enzyme purification with inhibition kinetics. It identifies noncompetitive inhibition for all compounds and shows that gabapentin has the strongest apparent inhibitory activity, while phenytoin produces a weaker but measurable effect under the assay conditions.
-
Dibutyryl-cAMP: From Signal Control to Translation
2026-09-20
Dibutyryl-cAMP, sodium salt offers translational researchers a controllable way to perturb cAMP-dependent signaling while preserving a disciplined distinction between pathway activation and disease relevance. This thought-leadership article connects PKA-oriented pharmacology with recent tau findings in mouse and human brain slice cultures, outlines a model-aware experimental strategy, and positions DBcAMP sodium salt as a practical tool for neurobiology and inflammation-focused research.
-
BMAL1 Phase Separation in Circadian Transcription
2026-09-19
Gao and colleagues identify BMAL1 as a phosphorylation-tunable phase-separating protein that organizes dynamic nuclear transcriptional hubs with CLOCK, p300, MED1, and E-box DNA. The study links the N-terminal intrinsically disordered region of BMAL1 to rhythmic transcription and behavioral clock function, providing a mechanistic explanation for why BMAL1 chromatin occupancy does not immediately produce peak transcription.
-
OSMI-1 O-GlcNAc Transferase Inhibitor Workflow
2026-09-18
Use OSMI-1 as a cell-permeable OGT perturbation tool to connect protein O-GlcNAc modification with trophoblast ferroptosis, iron handling, and syncytialization. This practical workflow combines dose-ranging, target-engagement controls, and HUWE1–TfR1 pathway readouts while keeping cytotoxicity and solvent effects distinguishable.
-
Prednisolone: GR Assays Beyond ERAD Hype
2026-09-18
Prednisolone is a synthetic glucocorticoid for mechanistic glucocorticoid signaling research, inflammation modulation, and assay controls. This guide distinguishes validated Prednisolone workflows from emerging ERAD-based degradation evidence and shows how to design interpretable cross-domain experiments.
-
DHODH Inhibition and TP53 in Nasopharyngeal Cancer
2026-09-17
Dong et al. identify pyrimidine metabolism and its rate-limiting enzyme DHODH as actionable vulnerabilities in nasopharyngeal carcinoma, showing that BAY2402234 suppresses tumor-cell growth, motility, and survival. The study further connects DHODH inhibition to TP53 signaling and provides a useful framework for integrating metabolic profiling with functional genetic validation.
-
Hexose Diphosphate: Metabolic Research Guide
2026-09-17
Hexose diphosphate is a water-soluble hexose phosphate used to investigate central carbon metabolism, glycolytic regulation, and energy homeostasis research. Its identity, solvent compatibility, and storage requirements should be verified before interpreting metabolic or inflammatory assay results.
-
ML-7 Hydrochloride for Cardiac I/R Research
2026-09-16
ML-7 hydrochloride provides a practical way to interrogate MLCK-dependent contractility, cardiomyocyte injury, and endothelial barrier regulation. This workflow-focused guide connects dose preparation and phosphorylation readouts with annexin-V mapping, proteomics, and ischemia/reperfusion injury research.
-
CK2 and ERK8 Inhibitor: Assay Attribution
2026-09-16
Explore how the small molecule inhibitor B7464 can be used to separate kinase-dependent signaling from direct effects on biomolecular condensates. Grounded in SARS-CoV-2 nucleocapsid phase-separation research, this guide presents an orthogonal assay strategy for rigorous biochemical interpretation.
-
Sildenafil Citrate in Proteoform-Aware Assays
2026-09-15
Build reproducible vascular assays around a nanomolar cGMP-specific phosphodiesterase type 5 inhibitor, then connect functional responses to ERK signaling and proteoform-aware interaction studies. This workflow distinguishes PDE5-driven biology from formulation, vehicle, timing, and native-membrane effects.
-
O-GlcNAc–HUWE1–TfR1 Axis in Preeclampsia
2026-09-15
The reference study identifies an O-GlcNAc–HUWE1–TfR1 pathway that links trophoblast ferroptosis, iron uptake, and syncytialization defects in preeclampsia. Its findings provide a mechanistic framework for studying how protein O-GlcNAc modification influences placental stress, while also highlighting the need for carefully controlled cellular and in vivo validation.
-
G-15: GPR30 Antagonist Workflow Guide
2026-09-14
Use G-15 to separate GPR30-driven estrogen signaling from classical ERα and ERβ activity in calcium, PI3K/Akt, proliferation, and osteoblast assays. This workflow translates a recent GPR30/PI3K/AKT osteoporosis study into practical pharmacology, with concentration planning, controls, and troubleshooting guidance.
-
Dinaciclib, VHL Loss, and Selective CC-RCC Targeting
2026-09-14
The reference study identifies a synthetic-lethal relationship between VHL deficiency and the cyclin-dependent kinase inhibitor Dinaciclib in clear cell renal cell carcinoma. Its combination of isogenic cell models, mechanistic assays, and an orthotopic patient-derived xenograft model supports VHL loss and proliferative state as important determinants of response, while also highlighting limitations that must be addressed before clinical translation.